Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34–0.54% (3.7–5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide −0.20% [95% CI −0.32; −0.07]; 1.2 mg liraglutide −0.15% [95% CI −0.27; −0.03]; 0.6 mg liraglutide −0.09% [95% CI −0.21; 0.03]). Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]). Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide −4.9 kg [95% CI −5.7; −4.2]; 1.2 mg liraglutide −3.6 kg [95% CI −4.3; −2.8]; 0.6 mg liraglutide −2.2 kg [95% CI −2.9; −1.5]). The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglutide 1.8 mg only (event rate ratio 2.22 [95% CI 1.13; 4.34]). CONCLUSIONS: Liraglutide added to insulin therapy reduced HbA1c levels, total insulin dose, and body weight in a population that was generally representative of subjects with type 1 diabetes, accompanied by increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thereby limiting clinical use in this group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The largest clinical trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions ($0.4%), decreases in weight ($5 kg), and reductions in insulin doses (71,72).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [71]
In the citing paper
“However, increased rates of hypoglycemia and ketosis were shown.”
In the citing paper
“The largest clinical trials in people with type 1 diabetes were conducted with liraglutide and showed decreases in HbA 1c at daily doses of 1.8 mg (0.2-0.4% [2-4 mmol/mol]), decreases in weight (5 kg), and reductions in insulin doses (257,258).”
In the citing paper
“GLP1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.[93][94][95][96]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [93]
In the citing paper
“Adding SGLT2 inhibitors at a lower than usual dose to insulin therapy in T1DM may reduce glucose variability and facilitate glucose control, thereby reducing insulin doses and hypoglycaemia.803”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [803]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“****EAC-confirmed malignant neoplasms were all skin cancers (two malignant melanomas; one basal cell carcinoma) using ADA classification of hypoglycemia (13).”
BackgroundMethodInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“drate levels may be reduced as a result of urinary excretion (23,24).”
BackgroundWeinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Self-citationDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Cited by
Items 301–347 of 347
Objetivos del tratamiento de la diabetes mellitus tipo 1
Cebada, A. B., da Silva, J. K. H., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.002 · Cited by 2
Protocolo terapéutico y seguimiento del paciente con diabetes mellitus tipo 1 y obesidad
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.006
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
Insulin Resistance in Type 1 Diabetes and Its Treatment Strategies
孙, 全. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153617
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetes aktuell · doi:10.1055/a-2539-0910
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01344-8
Jang, H. N., Hong, E. S., Yang, Y., Lee, S. O., Jang, M., Mari, A., Kwak, S. H., Park, K. S., Jang, H. C., & Jung, H. S. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0741
Stopyra, M., Feret, K., Andrzejczyk, A., Nafalska, N., Tomaszewska, A., Gadzinowska, J., Kokoszka, M., Chodór, M., Szpila, G., & Lewandowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3970
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Dai, H., Lee, Y., Radwan, R., Sheer, A., Hannon, T., Hayes, M. R., Sun, R. C., Bian, J., & Guo, J.-C. (2025) · medRxiv · doi:10.1101/2025.11.10.25339908
Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
Minsky, N. C., Olshanskiy, D., & Aharon‐Hananel, G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70389
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Hayek, A. A., Robert, A. A., Alburayk, A. K., Alwadai, A. N., Almutairi, A. M., Shabani, A. A., & Dawish, M. A. A. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998428827251223081042
Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
Mottl, A. K., Sawinski, D. L., & Bjornstad, P. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.022
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01446-x
Metabolic dysfunction and the use of adjunct medications in type 1 diabetes
Luk, A., Cheah, Y. S., Misra, S., & Salem, V. (2026) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000956
周, 玮. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641306
GLP-1 receptor agonists and acute diabetes complications in adults with type 1 diabetes
Dai, H., Lee, Y. A., Radwan, R. M., Sheer, A. J., Hannon, T. S., Hayes, M. R., Sun, R. C., Bian, J., & Guo, J. (2026) · iScience · doi:10.1016/j.isci.2026.115700
Popovic, D. S., Κender, Ζ., & Koufakis, T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70226
Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes
Andreasen, C. R., Vilsbøll, T., Aistrup, M. Ø., & Kloppenborg, J. T. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074286
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes
Innes, R., Petrie, J. R., & Dejgaard, T. F. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.002
Yazdanfard, P. D. W., Kosjerina, V., Wood-Kurland, H. K., Andersen, M. P., Hommel, E. E., Dejgaard, T. F., Nørgaard, K., Torp-Pedersen, C. T., & Sørensen, K. K. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101716 · Cited by 1
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.007
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3375
Ghanim, H., Srungavarapu, S. R., Dandona, P., & Chaudhuri, A. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.009
Lim, C.-E., Pasternak, B., Eliasson, B., Pazzagli, L., & Ueda, P. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101729
Ishtiaq, S., Malik, Z. M., & Ahmad, A. R. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70256
Hughes, M. S., & Pasquel, F. J. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.015
Kommentar zu Insulindosis-Reduktion unter Semaglutid bei Typ-1-Diabetes und Adipositas
Ritzel, R. A. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2855-8818
Selecting Pharmacologic Interventions for MASH
Pan, J. J., Horwich, B., Chahine, M., Gutierrez, J. A., & Saab, S. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10003-x
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
Refining metabolic‐response signals after liraglutide therapy in type 1 diabetes
Zheng, J., & Zhang, J. N. (2026) · Diabetic Medicine · doi:10.1111/dme.70417
Cheng, S.-A., & Lim, J. H. (2026) · Life · doi:10.3390/life16071135
Alkhushaym, N., Almutairi, W., ALANAZI, S., Balharith, R., Alhifany, A. A., & Musa, I. R. (2026) · Research Square · doi:10.21203/rs.3.rs-10216709/v1
Timmons, J. G., Ghanim, H., Boyle, J. G., Greenlaw, N., Chaudhuri, A., Batra, M., Lindsay, R. S., Jolly, L., Bonner, C., McConnachie, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71076
Almoallem, B., & Thalange, N. K. S. (2026) · Cureus · doi:10.7759/cureus.114782
Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications
Bloomgarden, Z. T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70427
Kitsios, K., & Trakatelli, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261486127
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z · Cited by 1
Matson, R. P., Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Diabetology · doi:10.3390/diabetology7100189
Decoding inflammation to target hybrid diabetes phenotypes
Rossi, G., Terranegra, A., Lunati, M. E., Pastore, I., Canova, L. P., Bucciarelli, L., Cimino, V., Loretelli, C., Nasr, M. B., Fiorina, P., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922969
Jang, R., Jang, M., Ruan, X., Jin, C., & Kim, W. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04199-0
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis
Barbosa, L., Oliveira, V. M. R., Ruelas, M. G., NASCIMENTO, B. R., Moreira, H. G., Nunes, M. D. C. P., Darrieux, F., Lópes, R. D., Boriani, G., & Lip, G. Y. H. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.10.052
Metadata
- Authors
- Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Mount Sinai Hospital (CA)
- Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
- Health Sciences Centre (CA)
- The Royal Melbourne Hospital (AU)
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Mathieu, Chantal
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-09
- Volume
- 39
- Issue
- 10
- Pages
- 1702-1710
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514658869
- Cited by
- 347
- References
- 26
- Citations by year
- 2026: 52 · 2025: 56 · 2024: 49 · 2023: 28 · 2022: 23 · 2021: 28 · 2020: 34 · 2019: 27 · 2018: 26 · 2017: 17 · 2016: 7
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Novo Nordisk A/S (NN9211-3919)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, insulin therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, GLP-1 receptor agonists, adjunctive therapy, drug safety, hypoglycemia, nausea, gastrointestinal adverse effects, drug discontinuation
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.